Literature DB >> 29419568

Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV.

Richard A Elion1,2, Keri N Althoff3, Jinbing Zhang3, Richard D Moore4, Stephen J Gange3, Mari M Kitahata5, Heidi M Crane5, Daniel R Drozd5, James H Stein6, Marina B Klein7,8, Joseph J Eron9, Michael J Silverberg10, William C Mathews11, Amy C Justice12,13, Timothy R Sterling14, Charles S Rabkin15, Angel M Mayor16, Daniel B Klein17, Michael A Horberg18, Ronald J Bosch19, Oghenowede Eyawo20,21, Frank J Palella22.   

Abstract

BACKGROUND: There is persistent confusion as to whether abacavir (ABC) increases the risk of myocardial infarction (MI), and whether such risk differs by type 1 (T1MI) or 2 (T2MI) MI in adults with HIV.
METHODS: Incident MIs in North American Cohort Collaboration on Research and Design participants were identified from 2001 to 2013. Discrete time marginal structural models addressed channeling biases and time-dependent confounding to estimate crude hazard ratio (HR) and adjusted hazard ratio (aHR) and 95% confidence intervals; analyses were performed for T1MI and T2MI separately. A sensitivity analysis evaluated whether Framingham risk score (FRS) modified the effect of ABC on MI occurrence.
RESULTS: Eight thousand two hundred sixty-five adults who initiated antiretroviral therapy contributed 29,077 person-years and 123 MI events (65 T1MI and 58 T2MI). Median follow-up time was 2.9 (interquartile range 1.4-5.1) years. ABC initiators were more likely to have a history of injection drug use, hepatitis C virus infection, hypertension, diabetes, impaired kidney function, hyperlipidemia, low (<200 cells/mm) CD4 counts, and a history of AIDS. The risk of the combined MI outcome was greater for persons who used ABC in the previous 6 months [aHR = 1.84 (1.17-2.91)]; and persisted for T1MI (aHR = 1.62 [1.01]) and T2MI [aHR = 2.11 (1.08-4.29)]. FRS did not modify the effect of ABC on MI (P = 0.14) and inclusion of FRS in the MSM did not diminish the effect of recent ABC use on the combined outcome.
CONCLUSIONS: Recent ABC use was associated with MI after adjustment for known risk factors and for FRS. However, screening for T1MI risks may not identify all or even most persons at risk of ABC use-associated MIs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29419568      PMCID: PMC5889316          DOI: 10.1097/QAI.0000000000001642

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  35 in total

1.  Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Authors:  Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore
Journal:  Int J Epidemiol       Date:  2007-01-08       Impact factor: 7.196

2.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner
Journal:  J Am Coll Cardiol       Date:  2012-09-05       Impact factor: 24.094

3.  Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Authors:  Roger J Bedimo; Andrew O Westfall; Henning Drechsler; Gabriela Vidiella; Pablo Tebas
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

4.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

5.  Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Authors:  Niels Obel; D K Farkas; G Kronborg; C S Larsen; G Pedersen; A Riis; C Pedersen; J Gerstoft; H T Sørensen
Journal:  HIV Med       Date:  2009-08-13       Impact factor: 3.180

6.  Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals.

Authors:  Julia L Marcus; Romain S Neugebauer; Wendy A Leyden; Chun R Chao; Lanfang Xu; Charles P Quesenberry; Daniel B Klein; William J Towner; Michael A Horberg; Michael J Silverberg
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

7.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

8.  Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Authors:  Signe Westring Worm; Caroline Sabin; Rainer Weber; Peter Reiss; Wafaa El-Sadr; Francois Dabis; Stephane De Wit; Matthew Law; Antonella D'Arminio Monforte; Nina Friis-Møller; Ole Kirk; Eric Fontas; Ian Weller; Andrew Phillips; Jens Lundgren
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

9.  Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.

Authors:  Caroline A Sabin; Peter Reiss; Lene Ryom; Andrew N Phillips; Rainer Weber; Matthew Law; Eric Fontas; Amanda Mocroft; Stephane de Wit; Colette Smith; Francois Dabis; Antonella d'Arminio Monforte; Wafaa El-Sadr; Jens D Lundgren
Journal:  BMC Med       Date:  2016-03-31       Impact factor: 8.775

10.  Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.

Authors:  Kunchok Dorjee; Sanjiv M Baxi; Arthur L Reingold; Alan Hubbard
Journal:  BMC Infect Dis       Date:  2017-10-27       Impact factor: 3.090

View more
  18 in total

Review 1.  Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Authors:  Sean G Kelly; Mary Clare Masters; Babafemi O Taiwo
Journal:  Infect Dis Clin North Am       Date:  2019-06-22       Impact factor: 5.982

Review 2.  Epidemiology, pathophysiology, and prevention of heart failure in people with HIV.

Authors:  Arjun Sinha; Matthew Feinstein
Journal:  Prog Cardiovasc Dis       Date:  2020-01-24       Impact factor: 8.194

Review 3.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

Review 4.  HIV infection and coronary heart disease: mechanisms and management.

Authors:  Priscilla Y Hsue; David D Waters
Journal:  Nat Rev Cardiol       Date:  2019-06-10       Impact factor: 32.419

5.  Subclinical Vascular Disease in Children With Human Immunodeficiency Virus in Uganda Is Associated With Intestinal Barrier Dysfunction.

Authors:  Sahera Dirajlal-Fargo; Zainab Albar; Emily Bowman; Danielle Labbato; Abdus Sattar; Christine Karungi; Chris T Longenecker; Rashida Nazzinda; Nicholas Funderburg; Cissy Kityo; Victor Musiime; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

6.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

7.  Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies.

Authors:  Kunchok Dorjee; Tsering Choden; Sanjiv M Baxi; Craig Steinmaus; Arthur L Reingold
Journal:  Int J Antimicrob Agents       Date:  2018-07-21       Impact factor: 5.283

8.  Effects of HIV Infection on Arterial Endothelial Function: Results From a Large Pooled Cohort Analysis.

Authors:  James H Stein; Noah Kime; Claudia E Korcarz; Heather Ribaudo; Judith S Currier; Joseph C Delaney
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-17       Impact factor: 8.311

9.  Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.

Authors:  Paul E Sax; Jürgen K Rockstroh; Anne F Luetkemeyer; Yazdan Yazdanpanah; Douglas Ward; Benoit Trottier; Armin Rieger; Hui Liu; Rima Acosta; Sean E Collins; Diana M Brainard; Hal Martin
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

10.  Cardiovascular disease and prevention among people living with HIV in South Florida.

Authors:  Fahim Pyarali; Roumen Iordanov; Bertrand Ebner; Jelani Grant; Louis Vincent; Alexander Toirac; Tahir Haque; Gerardo Zablah; Kunal Kapoor; Alexis Powell; Catherine Boulanger; Barry Hurwitz; Maria Alcaide; Claudia Martinez
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.